AR110101A1 - Miembros de unión (2) - Google Patents
Miembros de unión (2)Info
- Publication number
- AR110101A1 AR110101A1 ARP170101707A ARP170101707A AR110101A1 AR 110101 A1 AR110101 A1 AR 110101A1 AR P170101707 A ARP170101707 A AR P170101707A AR P170101707 A ARP170101707 A AR P170101707A AR 110101 A1 AR110101 A1 AR 110101A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- antibody molecule
- lag
- molecule according
- binding site
- Prior art date
Links
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 abstract 5
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 abstract 5
- 108010074708 B7-H1 Antigen Proteins 0.000 abstract 3
- 102000008096 B7-H1 Antigen Human genes 0.000 abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000012258 culturing Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/50—Colon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464401—Neoantigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicación 1: Una molécula de anticuerpo que se une al ligando de muerte programada 1 (PD-L1) y gen de activación de linfocitos 3 (LAG-3), en el que la molécula de anticuerpo comprende: (i) un sitio de unión al antígeno basado en CDR para PD-L1; y (ii) un sitio de unión al antígeno LAG-3 ubicado en el dominio CH3 de la molécula de anticuerpo, en la que el sitio de unión de LAG-3 comprende las secuencias de aminoácidos WDEPWGED (SEQ ID Nº 1) y PYDRWVWPDE (SEQ ID Nº 3), y en la que la secuencia de aminoácidos WDEPWGED se ubica en un primer bucle estructural del dominio CH3 y la secuencia de aminoácidos PYDRWVWPDE se ubica en un segundo bucle estructural del dominio CH3. Reivindicación 4: Una molécula de anticuerpo de acuerdo con cualquiera de las reivindicaciones 1 a 3, en la que el sitio de unión al antígeno LAG-3 además comprende una de las siguientes secuencias: (i) SNGQPENNY (SEQ ID Nº 2, 8 y 18); (ii) SNGQPEDNY (SEQ ID Nº 13); (iii) SNGYPEIEF (SEQ ID Nº 23); (iv) SNGIPEWNY (SEQ ID Nº 28); (v) SNGYAEYNY (SEQ ID Nº 33); (vi) SNGYKEENY (SEQ ID Nº 38); (vii) SNGVPELNV (SEQ ID Nº 43); o (viii) SNGYQEDNY (SEQ ID Nº 48). Reivindicación 29: Un ácido nucleico que codifica una molécula de anticuerpo de acuerdo con cualquiera de las reivindicaciones 1 a 28. Reivindicación 32: Un método de producir una molécula de anticuerpo de acuerdo con cualquiera de las reivindicaciones 1 a 28, que comprende cultivar la célula huésped recombinante de la reivindicación 31 en condiciones para la producción de la molécula de anticuerpo. Reivindicación 34: Una composición farmacéutica que comprende una molécula de anticuerpo de acuerdo con cualquiera de las reivindicaciones 1 a 28 y un excipiente farmacéuticamente aceptable. Reivindicación 36: Un método de tratamiento de cáncer en un paciente, en el que el método comprende administrar al paciente una cantidad terapéuticamente efectiva de una molécula de anticuerpo de acuerdo con cualquiera de las reivindicaciones 1 a 28.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662352482P | 2016-06-20 | 2016-06-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR110101A1 true AR110101A1 (es) | 2019-02-27 |
Family
ID=59631719
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP170101707A AR110101A1 (es) | 2016-06-20 | 2017-06-21 | Miembros de unión (2) |
Country Status (24)
Country | Link |
---|---|
US (2) | US11214620B2 (es) |
EP (2) | EP3472207B1 (es) |
JP (2) | JP7085709B2 (es) |
KR (2) | KR102664891B1 (es) |
CN (1) | CN109563171B (es) |
AR (1) | AR110101A1 (es) |
AU (1) | AU2017283181B2 (es) |
BR (1) | BR112018076519A8 (es) |
CA (1) | CA3027612A1 (es) |
CY (1) | CY1124232T1 (es) |
DK (1) | DK3472207T3 (es) |
ES (1) | ES2858091T3 (es) |
HR (1) | HRP20210602T1 (es) |
HU (1) | HUE053742T2 (es) |
IL (1) | IL263730B2 (es) |
LT (1) | LT3472207T (es) |
MX (1) | MX2018016320A (es) |
PL (1) | PL3472207T3 (es) |
PT (1) | PT3472207T (es) |
RS (1) | RS61705B1 (es) |
SG (1) | SG11201811064TA (es) |
SI (1) | SI3472207T1 (es) |
TW (1) | TW201803906A (es) |
WO (1) | WO2017220569A1 (es) |
Families Citing this family (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
US10519237B2 (en) | 2014-03-12 | 2019-12-31 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
KR20230097209A (ko) | 2014-03-12 | 2023-06-30 | 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 | Cns의 질환 및 손상을 치료하기 위한 전신적 조절 t 세포 수준 또는 활성의 감소 |
US10618963B2 (en) | 2014-03-12 | 2020-04-14 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
TWI756187B (zh) | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗lag3抗體及其用途 |
NZ743881A (en) | 2016-02-06 | 2023-11-24 | Epimab Biotherapeutics Inc | Fabs-in-tandem immunoglobulin and uses thereof |
CA3027612A1 (en) * | 2016-06-20 | 2017-12-28 | F-Star Delta Limited | Binding molecules binding pd-l1 and lag-3 |
WO2017220555A1 (en) | 2016-06-20 | 2017-12-28 | F-Star Beta Limited | Lag -3 binding members |
US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
MA46814B2 (fr) | 2017-02-10 | 2022-09-30 | Regeneron Pharma | Anticorps anti-lag3 radiomarqués pour imagerie immuno-pet |
CN110678200B (zh) | 2017-05-30 | 2024-05-17 | 百时美施贵宝公司 | 包含抗lag-3抗体或抗lag-3抗体和抗pd-1或抗pd-l1抗体的组合物 |
HRP20231457T1 (hr) | 2017-05-30 | 2024-05-10 | Bristol-Myers Squibb Company | Liječenje lag-3-pozitivnih tumora |
EP4245375A3 (en) | 2017-05-30 | 2023-12-06 | Bristol-Myers Squibb Company | Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent |
US11548948B2 (en) | 2017-12-19 | 2023-01-10 | F-Star Therapeutics Limited | FC binding fragments comprising a PD-L1 antigen-binding site |
WO2019129054A1 (zh) * | 2017-12-27 | 2019-07-04 | 信达生物制药(苏州)有限公司 | 三链抗体、其制备方法及其用途 |
CN109970856B (zh) | 2017-12-27 | 2022-08-23 | 信达生物制药(苏州)有限公司 | 抗lag-3抗体及其用途 |
EP3758751A4 (en) * | 2018-02-28 | 2021-11-17 | Wuxi Biologics Ireland Limited. | MONOCLONAL ANTIBODIES AGAINST HUMAN LAG-3, METHOD OF MANUFACTURING AND USING THEREOF |
CN110343178B (zh) * | 2018-04-03 | 2022-07-22 | 上海开拓者生物医药有限公司 | 抗人lag-3单克隆抗体及其应用 |
AU2019263850A1 (en) * | 2018-05-03 | 2020-11-19 | Shanghai Epimab Biotherapeutics Co., Ltd. | High affinity antibodies to PD-1 and LAG-3 and bispecific binding proteins made therefrom |
SG11202101551TA (en) * | 2018-05-17 | 2021-03-30 | Immunome Inc | Ch3 domain epitope tags |
WO2019246142A1 (en) * | 2018-06-18 | 2019-12-26 | Haiming Chen | Soluble bispecific fusion proteins for cancer immunotherapy |
GB201811403D0 (en) * | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Antibody molecules |
EP3826660A1 (en) | 2018-07-26 | 2021-06-02 | Bristol-Myers Squibb Company | Lag-3 combination therapy for the treatment of cancer |
SG11202102864XA (en) | 2018-10-19 | 2021-05-28 | Bristol Myers Squibb Co | Combination therapy for melanoma |
IL279670B2 (en) * | 2018-12-17 | 2024-09-01 | Illumina Inc | flow chambers and flooring kits |
TWI756621B (zh) * | 2019-01-25 | 2022-03-01 | 大陸商信達生物製藥(蘇州)有限公司 | 新型雙特異性抗體分子以及同時結合pd-l1和lag-3的雙特異性抗體 |
EP3715375A1 (en) | 2019-03-23 | 2020-09-30 | Ablevia biotech GmbH | Compound for the prevention or treatment of pre-eclampsia |
EP3715374A1 (en) | 2019-03-23 | 2020-09-30 | Ablevia biotech GmbH | Compound for the sequestration of undesirable antibodies in a patient |
EP3715376A1 (en) | 2019-03-23 | 2020-09-30 | Ablevia biotech GmbH | Compound for the prevention or treatment of myasthenia gravis |
US11986536B2 (en) | 2019-03-23 | 2024-05-21 | Ablevia Biotech Gmbh | Compound for the sequestration of undesirable antibodies in a patient |
EP3725370A1 (en) | 2019-04-19 | 2020-10-21 | ImmunoBrain Checkpoint, Inc. | Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease |
MX2021013943A (es) * | 2019-05-14 | 2022-01-04 | F Star Therapeutics Ltd | Pautas posologicas para la administracion de un anticuerpo biespecifico frente a lag-3/pd-l1. |
KR20220016156A (ko) | 2019-05-30 | 2022-02-08 | 브리스톨-마이어스 스큅 컴퍼니 | 면역-종양학 요법에의 적합성을 위한 다종양 유전자 시그너쳐 |
EP3976832A1 (en) | 2019-05-30 | 2022-04-06 | Bristol-Myers Squibb Company | Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy |
WO2020243570A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Cell localization signature and combination therapy |
WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
US20220348653A1 (en) | 2019-09-22 | 2022-11-03 | Bristol-Myers Squibb Company | Quantitative Spatial Profiling for LAG-3 Antagonist Therapy |
US20220348664A1 (en) * | 2019-09-26 | 2022-11-03 | WuXi Biologics Ireland Limited | A novel anti-pd-l1/anti-lag-3 bispecific antibody and uses thereof |
WO2021092220A1 (en) | 2019-11-06 | 2021-05-14 | Bristol-Myers Squibb Company | Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy |
WO2021092221A1 (en) | 2019-11-06 | 2021-05-14 | Bristol-Myers Squibb Company | Methods of identifying a subject with a tumor suitable for a checkpoint inhibitor therapy |
AU2020380384A1 (en) | 2019-11-08 | 2022-05-26 | Bristol-Myers Squibb Company | LAG-3 antagonist therapy for melanoma |
CN110950966B (zh) * | 2019-12-13 | 2020-12-11 | 启辰生生物科技(珠海)有限公司 | 融合蛋白、编码核酸和细胞及用途 |
KR20220119694A (ko) * | 2019-12-23 | 2022-08-30 | 마크로제닉스, 인크. | 암 치료를 위한 요법 |
AU2021206202A1 (en) | 2020-01-07 | 2022-06-30 | Board Of Regents, The University Of Texas System | Improved human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy |
EP4100426A1 (en) | 2020-02-06 | 2022-12-14 | Bristol-Myers Squibb Company | Il-10 and uses thereof |
AU2021269832B2 (en) * | 2020-05-12 | 2024-09-19 | Astrazeneca Ab | Methods and combinations for the treatment of cancer using immune checkpoint inhibitor antibodies |
EP4178611A1 (en) | 2020-07-07 | 2023-05-17 | BioNTech SE | Therapeutic rna for hpv-positive cancer |
KR20230058442A (ko) | 2020-08-28 | 2023-05-03 | 브리스톨-마이어스 스큅 컴퍼니 | 간세포성 암종에 대한 lag-3 길항제 요법 |
WO2022047412A1 (en) | 2020-08-31 | 2022-03-03 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
US20230381334A1 (en) | 2020-09-23 | 2023-11-30 | Ablevia Biotech Gmbh | Compound for the sequestration of undesirable antibodies in a patient |
JP2023548051A (ja) | 2020-10-23 | 2023-11-15 | ブリストル-マイヤーズ スクイブ カンパニー | 肺がんのためのlag-3アンタゴニスト療法 |
WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
TW202245808A (zh) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | 用於治療癌症之治療性rna |
WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
MX2023007650A (es) | 2020-12-28 | 2023-09-11 | Bristol Myers Squibb Co | Metodos de tratamiento de tumores. |
JP2024503265A (ja) | 2020-12-28 | 2024-01-25 | ブリストル-マイヤーズ スクイブ カンパニー | 抗体組成物およびその使用の方法 |
JP2024514245A (ja) | 2021-03-29 | 2024-03-29 | ジュノー セラピューティクス インコーポレイテッド | チェックポイント阻害剤療法とcar t細胞療法との組合せを用いた投薬および処置のための方法 |
US20240285740A1 (en) | 2021-05-12 | 2024-08-29 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating cancer |
AU2022312698A1 (en) | 2021-07-13 | 2024-01-25 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
TW202333802A (zh) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | 用於肺癌之治療性rna(二) |
IL309227A (en) | 2021-10-29 | 2024-02-01 | Bristol Myers Squibb Co | LAG-3 antagonist therapy for hematological cancer |
IL314050A (en) | 2022-01-26 | 2024-09-01 | Bristol Myers Squibb Co | Combined treatment method for hepatocellular carcinoma |
AU2023226078A1 (en) | 2022-02-25 | 2024-08-22 | Bristol-Myers Squibb Company | Combination therapy for colorectal carcinoma. |
WO2023168404A1 (en) | 2022-03-04 | 2023-09-07 | Bristol-Myers Squibb Company | Methods of treating a tumor |
WO2023170606A1 (en) | 2022-03-08 | 2023-09-14 | Alentis Therapeutics Ag | Use of anti-claudin-1 antibodies to increase t cell availability |
WO2023178329A1 (en) | 2022-03-18 | 2023-09-21 | Bristol-Myers Squibb Company | Methods of isolating polypeptides |
WO2023235847A1 (en) | 2022-06-02 | 2023-12-07 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
WO2024107731A2 (en) * | 2022-11-14 | 2024-05-23 | Ablexis, Llc | Anti-pd-l1 antibodies |
WO2024116140A1 (en) | 2022-12-01 | 2024-06-06 | Medimmune Limited | Combination therapy for treatment of cancer comprising anti-pd-l1 and anti-cd73 antibodies |
WO2024126457A1 (en) | 2022-12-14 | 2024-06-20 | Astellas Pharma Europe Bv | Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and immune checkpoint inhibitors |
WO2024137776A1 (en) | 2022-12-21 | 2024-06-27 | Bristol-Myers Squibb Company | Combination therapy for lung cancer |
WO2024173876A1 (en) | 2023-02-17 | 2024-08-22 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-lag3 antibodies for immuno-pet imaging |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2245404C3 (de) | 1972-09-15 | 1978-08-31 | Robert Bosch Gmbh, 7000 Stuttgart | Massewiderstand, insbesondere für Zündkerzen, sowie Verfahren zur Herstellung desselben |
JPS531908B2 (es) | 1973-11-12 | 1978-01-23 | ||
JPS5746634B2 (es) | 1974-05-10 | 1982-10-04 | ||
JPS5146628A (ja) | 1974-10-17 | 1976-04-21 | Nippon Denso Co | Teikoirisupaakupuragu |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
DE19818214A1 (de) | 1998-04-24 | 1999-10-28 | Bosch Gmbh Robert | Zündkerze für eine Brennkraftmaschine |
JP4578025B2 (ja) | 2001-07-06 | 2010-11-10 | 日本特殊陶業株式会社 | スパークプラグ |
RS50785B (sr) | 2005-01-05 | 2010-08-31 | F-Star Biotechnologische Forschungs-Und Entwicklungsges M.B.H. | Domeni sintetskih imunoglobulina sa svojstvima vezivanja, konstruisani u svojstvima molekula, koji se razlikuju od regiona, koji određuju komplementarnost |
SI1907424T1 (sl) * | 2005-07-01 | 2015-12-31 | E. R. Squibb & Sons, L.L.C. | Humana monoklonska protitelesa proti programiranem smrtnem ligandu 1 (PD-L1) |
HUE066143T2 (hu) | 2007-06-26 | 2024-07-28 | F Star Therapeutics Ltd | Kötõágensek megjelenítése |
EP2113255A1 (en) | 2008-05-02 | 2009-11-04 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Cytotoxic immunoglobulin |
AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
EP2407487A1 (en) * | 2010-07-14 | 2012-01-18 | F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. | Multispecific modular antibody |
EP2546268A1 (en) | 2011-07-13 | 2013-01-16 | F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. | Internalising immunoglobulin |
UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
JP5276742B1 (ja) | 2012-08-09 | 2013-08-28 | 日本特殊陶業株式会社 | 点火プラグ |
NZ711355A (en) | 2013-03-15 | 2020-06-26 | Glaxosmithkline Ip Dev Ltd | Anti-lag-3 binding proteins |
EP3757130A1 (en) * | 2013-09-26 | 2020-12-30 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
WO2015138920A1 (en) * | 2014-03-14 | 2015-09-17 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
JP5902757B2 (ja) | 2014-06-24 | 2016-04-13 | 日本特殊陶業株式会社 | スパークプラグ |
WO2015198312A1 (en) | 2014-06-24 | 2015-12-30 | Ccam Therapeutics Ltd. | Compositions comprising antibodies to ceacam-1 and lag-3 for cancer therapy |
TWI693232B (zh) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法 |
EP3178139A1 (en) | 2014-08-10 | 2017-06-14 | Federal-Mogul Ignition Company | Spark plug with improved seal |
JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
SG11201708334RA (en) | 2015-05-04 | 2017-11-29 | Pieris Pharmaceuticals Gmbh | Anti-cancer fusion polypeptide |
RU2017142008A (ru) | 2015-05-21 | 2019-06-24 | Эллигейтор Биосайенс Аб | Новые полипептиды |
TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
JP6025921B1 (ja) | 2015-06-22 | 2016-11-16 | 日本特殊陶業株式会社 | スパークプラグ |
EP3322433B1 (en) | 2015-07-15 | 2023-05-31 | Pieris Pharmaceuticals GmbH | Novel proteins specific for lag-3 |
CN108348601B (zh) | 2015-07-22 | 2022-05-17 | 索伦托药业有限公司 | 与lag3结合的抗体治疗剂 |
KR20180035906A (ko) | 2015-08-07 | 2018-04-06 | 피어이스 파마슈티컬즈 게엠베하 | Lag-3 및 pd-1에 특이적인 신규 융합 폴리펩타이드 |
KR101782487B1 (ko) | 2015-09-24 | 2017-09-27 | 재단법인 목암생명과학연구소 | 신규 항-메소텔린 항체 및 이를 포함하는 조성물 |
TWI756187B (zh) | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗lag3抗體及其用途 |
GB201519481D0 (en) | 2015-11-04 | 2015-12-16 | Cancer Rec Tech Ltd | Immunomodulatory antibodies |
EA201891165A1 (ru) | 2015-11-18 | 2018-11-30 | Мерк Шарп И Доум Корп. | Молекулы, связывающие pd1 и/или lag3 |
WO2017087901A2 (en) | 2015-11-19 | 2017-05-26 | Sutro Biopharma, Inc. | Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies |
JP7022993B2 (ja) | 2016-01-11 | 2022-02-21 | インヒブルクス インコーポレイテッド | 多価かつ多重特異性の41bb結合融合タンパク質 |
RU2018139339A (ru) | 2016-04-22 | 2020-05-22 | Эллигейтор Биосайенс Аб | Новые биспецифические полипептиды против cd137 |
KR102531889B1 (ko) | 2016-06-20 | 2023-05-17 | 키맵 리미티드 | 항-pd-l1 및 il-2 사이토카인 |
WO2017220555A1 (en) | 2016-06-20 | 2017-12-28 | F-Star Beta Limited | Lag -3 binding members |
CA3027612A1 (en) * | 2016-06-20 | 2017-12-28 | F-Star Delta Limited | Binding molecules binding pd-l1 and lag-3 |
US9567399B1 (en) * | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
WO2018017673A1 (en) | 2016-07-20 | 2018-01-25 | Stcube, Inc. | Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated pd-l1 |
NZ751956A (en) | 2016-09-23 | 2022-01-28 | Merus Nv | Binding molecules that modulate a biological activity expressed by a cell |
GB201700345D0 (en) | 2017-01-09 | 2017-02-22 | F-Star Beta Ltd | Conditional agonists of immune responses |
CA3071211A1 (en) | 2017-08-04 | 2019-02-07 | Genmab A/S | Binding agents binding to pd-l1 and cd137 and use thereof |
US11548948B2 (en) | 2017-12-19 | 2023-01-10 | F-Star Therapeutics Limited | FC binding fragments comprising a PD-L1 antigen-binding site |
GB201811404D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-CD137 Antibodies |
-
2017
- 2017-06-20 CA CA3027612A patent/CA3027612A1/en active Pending
- 2017-06-20 EP EP17752291.9A patent/EP3472207B1/en active Active
- 2017-06-20 WO PCT/EP2017/065073 patent/WO2017220569A1/en unknown
- 2017-06-20 HU HUE17752291A patent/HUE053742T2/hu unknown
- 2017-06-20 PL PL17752291T patent/PL3472207T3/pl unknown
- 2017-06-20 ES ES17752291T patent/ES2858091T3/es active Active
- 2017-06-20 CN CN201780048977.2A patent/CN109563171B/zh active Active
- 2017-06-20 MX MX2018016320A patent/MX2018016320A/es unknown
- 2017-06-20 LT LTEP17752291.9T patent/LT3472207T/lt unknown
- 2017-06-20 RS RS20210453A patent/RS61705B1/sr unknown
- 2017-06-20 US US16/311,604 patent/US11214620B2/en active Active
- 2017-06-20 IL IL263730A patent/IL263730B2/en unknown
- 2017-06-20 BR BR112018076519A patent/BR112018076519A8/pt unknown
- 2017-06-20 DK DK17752291.9T patent/DK3472207T3/da active
- 2017-06-20 TW TW106120589A patent/TW201803906A/zh unknown
- 2017-06-20 PT PT177522919T patent/PT3472207T/pt unknown
- 2017-06-20 EP EP20213956.4A patent/EP3858858A1/en active Pending
- 2017-06-20 SI SI201730684T patent/SI3472207T1/sl unknown
- 2017-06-20 KR KR1020237006538A patent/KR102664891B1/ko active IP Right Grant
- 2017-06-20 JP JP2019518147A patent/JP7085709B2/ja active Active
- 2017-06-20 AU AU2017283181A patent/AU2017283181B2/en active Active
- 2017-06-20 KR KR1020197001122A patent/KR20190019144A/ko active IP Right Grant
- 2017-06-20 SG SG11201811064TA patent/SG11201811064TA/en unknown
- 2017-06-21 AR ARP170101707A patent/AR110101A1/es unknown
-
2021
- 2021-04-13 CY CY20211100319T patent/CY1124232T1/el unknown
- 2021-04-15 HR HRP20210602TT patent/HRP20210602T1/hr unknown
- 2021-11-23 US US17/533,230 patent/US20220185894A1/en active Pending
-
2022
- 2022-03-28 JP JP2022052202A patent/JP7464644B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR110101A1 (es) | Miembros de unión (2) | |
AR111203A1 (es) | Inmunoconjugados | |
AR110017A1 (es) | Anticuerpos de pd-1 y usos de estos | |
TWI659967B (zh) | 包括胃腸癌和胃癌的幾種腫瘤的新型免疫療法 | |
AR087567A1 (es) | Anticuerpos anti-tie2 y usos de los mismos | |
FI3389699T3 (fi) | Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja | |
US20220241428A1 (en) | Macrophage specific engager compositions and methods of use thereof | |
US11883398B2 (en) | Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy | |
JP2019526273A5 (es) | ||
AR105313A1 (es) | Anticuerpo anti-cd137 terapéutico | |
AR085281A1 (es) | Moduladores de la proteina tirosina quinasa 7 (ptk7) y metodos para su uso | |
AR109264A1 (es) | Proteínas de unión semejantes a anticuerpo biespecíficas que se unen específicamente a cd3 y cd123 | |
AR088455A1 (es) | Anticuerpos que antagonizan cd40l | |
RU2013155455A (ru) | Антитела для лечения раковых заболеваний, при которых эскспрессируется клаудин 6 | |
AR115769A1 (es) | Moléculas de unión a mesotelina y cd137 | |
CL2021002168A1 (es) | Péptido asociado a tumor; ácido nucleico; vector de expresión; célula huésped recombinante; método para producir el péptido; linfocitos t activados y su método de producción; anticuerpo; tcr; uso para tratar el cáncer; kit y composición farmacéutica; método para producir vacuna; y áptaro (divisional solicitud no. 201702407). | |
JP2019517508A5 (es) | ||
MX2021012004A (es) | Composiciones y metodos para preparar composiciones de celulas t y usos de las mismas. | |
AR123537A1 (es) | Anticuerpo contra hla-dq2.5 y su uso para el tratamiento de la enfermedad celíaca | |
HRP20210152T1 (hr) | Bispecifična antitijela za uporabu u imunoterapiji raka | |
AR095499A1 (es) | ANTICUERPOS MONOCLONALES CONTRA ANTITROMBINA b | |
MX2022009355A (es) | Anticuerpo anti-mdr1 y uso del mismo. | |
RU2010136988A (ru) | Антигенсвязывающие полипептиды против дегенерации хряща | |
RU2020115161A (ru) | Днк моноклональных антител против ctla-4 для лечения и профилактики рака | |
AR083971A1 (es) | Anticuerpos antiproliferacion humanizados homogeneos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |